All In Biotech

Drug Trial Radar · NCT07644377

Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Jan 31, 2031

Study completion Jan 31, 2031

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but severe complication of acute pulmonary embolism, characterized by persistent obstruction of the pulmonary arteries by organized thrombi and secondary microvasculopathy. International guidelines recommend a multimodal approach combining pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA), and medical treatment with riociguat, to address the full spectrum of CTEPH lesions. BPA and riociguat are recommended for symptomatic patients with inoperable CTEPH or persistent pulmonary hypertension after PEA. Riociguat is administered before BPA to reduce periprocedural complications by improving pulmonary hemodynamics. While this pre-BPA strategy is well established, post-BPA management is poorly studied, especially in patients achieving therapeutic goals, defined as WHO functional class I or II and near-normal resting pulmonary hemodynamics (70 to 80% of cases). In such cases, riociguat monotherapy is often continued long-term, despite its cost, burden, and potential side effects, which may negatively impact patients' quality of life. Retrospective single-center studies suggest that discontinuation of medical treatment does not lead to significant clinical deterioration. Therefore, we propose conducting a multicenter trial using a PROBE (prospective, randomized, open-label, blinded endpoint) design and a Bayesian approach to test if stopping riociguat monotherapy after successful BPA is associated with an acceptably low risk of clinical worsening over a follow-up period of at least one year compared to continuation. The trial will also assess the cost-effectiveness of riociguat discontinuation.

Conditions

  • CTEPH

Interventions

  • Discontinuation of riociguatDrug

    Discontinuation of riociguat after randomization

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate whether the discontinuation of riociguat monotherapy after successful BPA in CTEPH patients is associated with an acceptably low risk of clinical worsening compared to continuationTime frame: At the longest follow-up, minimum 12 months

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • CHU Angers

    Angers, France

  • Hôpital Haut Levêque

    Bordeaux, France

  • Hôpital de la Cavale blanche

    Brest, France

  • CHU Caen

    Caen, France

  • Hôpital Gabriel Montpied

    Clermont-Ferrand, France

  • CHU Dijon Bourgogne

    Dijon, France

  • CHU Grenoble Alpes

    Grenoble, France

  • Hôpital Bicêtre

    Le Kremlin-Bicêtre, France

  • Institut Cœur-Poumon

    Lille, France

  • Hôpital de la Timone

    Marseille, France

  • Hôpital Nord

    Marseille, France

  • CHU Montpellier

    Montpellier, France

  • Hôpital Laënnec

    Nantes, France

  • Hôpital Européen Georges Pompidou

    Paris, France

  • CHU Poitiers

    Poitiers, France

  • Hôpital Pontchaillou

    Rennes, France

  • CHU Rouen

    Rouen, France

  • CHU Saint Etienne

    Saint-Etienne, France

  • Nouvel Hôpital Civil

    Strasbourg, France

  • Hôpital Larrey

    Toulouse, France

  • Hôpital Bretonneau

    Tours, France

  • Hôpital Brabois

    Vandœuvre-lès-Nancy, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.